- Home
- IBOC vs PRAX Comparison
IBOC vs PRAX Comparison
Compare IBOC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBOC
- PRAX
- Stock Information
- Founded
- IBOC 1966
- PRAX 2015
- Country
- IBOC United States
- PRAX United States
- Employees
- IBOC N/A
- PRAX N/A
- Industry
- IBOC Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- IBOC Finance
- PRAX Health Care
- Exchange
- IBOC Nasdaq
- PRAX Nasdaq
- Market Cap
- IBOC 4.2B
- PRAX 4.0B
- IPO Year
- IBOC N/A
- PRAX 2020
- Fundamental
- Price
- IBOC $68.14
- PRAX $173.07
- Analyst Decision
- IBOC
- PRAX Strong Buy
- Analyst Count
- IBOC 0
- PRAX 13
- Target Price
- IBOC N/A
- PRAX $202.85
- AVG Volume (30 Days)
- IBOC 195.5K
- PRAX 1.4M
- Earning Date
- IBOC 11-04-2025
- PRAX 11-10-2025
- Dividend Yield
- IBOC 2.05%
- PRAX N/A
- EPS Growth
- IBOC 1.85
- PRAX N/A
- EPS
- IBOC 6.61
- PRAX N/A
- Revenue
- IBOC $808,643,000.00
- PRAX $7,765,000.00
- Revenue This Year
- IBOC N/A
- PRAX N/A
- Revenue Next Year
- IBOC N/A
- PRAX $20.00
- P/E Ratio
- IBOC $10.34
- PRAX N/A
- Revenue Growth
- IBOC 1.28
- PRAX 338.45
- 52 Week Low
- IBOC $54.11
- PRAX $26.70
- 52 Week High
- IBOC $76.91
- PRAX $205.89
- Technical
- Relative Strength Index (RSI)
- IBOC 51.39
- PRAX 77.03
- Support Level
- IBOC $65.60
- PRAX $164.75
- Resistance Level
- IBOC $66.99
- PRAX $192.96
- Average True Range (ATR)
- IBOC 1.55
- PRAX 12.54
- MACD
- IBOC 0.10
- PRAX 11.28
- Stochastic Oscillator
- IBOC 77.95
- PRAX 78.90
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.